Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Yuhei Endo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6374-9607; OpenAlex author ID A5101087900. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 6

  1. DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is Associated With Poor Prognosis. Co-author DOI 10.1097/mpa.0000000000002650↗
  2. Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. Co-author DOI 10.1038/s41598-023-31051-7↗
  3. Genome‑wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant metastasis and prognosis potential. Co-author DOI 10.3892/ijo.2022.5351↗
  4. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Co-author DOI 10.1038/s41598-021-00060-9↗
  5. A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.06.012↗
  6. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0227366↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fumiaki Watanabe · 6 shared papers, 2019–2026 · strength 0.90
  2. Toshiki Rikiyama · 6 shared papers, 2019–2026 · strength 0.90
  3. Koetsu Inoue · 1 shared paper, 2026 · strength 0.28
  4. Naoya Kasahara · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.